From the AP story, then:
. . . .Merck and Bristol-Myers Squibb will run a mid-stage clinical trial of a drug regimen designed to treat the most common type of the hepatitis C virus.We will keep you posted -- as ever. But I'd bet that a good portion of this "toughest to treat" market will be serviced by some other pharma(s)' lead candidate, come 2016 or so.
The trial will study a combination of Bristol's drug daclatasvir, and Merck's MK-5172. Merck will run the trial in which patients with genotype 1 hepatitis C will be monitored. That is both the most common type of the virus and the toughest to treat. . . .
No comments:
Post a Comment